Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,710 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Disorder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

NCT01429740
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-05180999, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses

NCT00494650
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive behavioral therapy (CBT), Brief PTSD treatment
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Monmouth Junction, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT00498550
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Abuse
Interventions
Clozapine, Treatment as usual
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Kansas City, Missouri • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Cannabidiol and ∆-9-THC in Humans

NCT01180374
View directory record Official record
Conditions
Healthy
Interventions
Cannabidiol, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

NCT06107803
View directory record Official record
Conditions
Negative Symptoms in Schizophrenia
Interventions
Roluperidone 64 mg, Olanzapine 10 MG
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia

NCT04309370
View directory record Official record
Conditions
Schizophrenia
Interventions
20 Hz rTMS
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 5, 2026, 9:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)

NCT06360562
View directory record Official record
Conditions
Mood Disorders, Anxiety Disorders, Psychotic Disorders
Interventions
Resilience Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

NCT02811939
View directory record Official record
Conditions
Healthy
Interventions
Active Dronabinol, Active Pregnenolone, Placebo Dronabinol, Placebo Pregnenolone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients

NCT00295139
View directory record Official record
Conditions
Schizophrenia, Mood Disorders, Substance Dependence
Interventions
Behavioral Treatment for Substance Abuse in SPMI (BTSAS), Supportive Treatment in Addiction Recovery (STAR), Critical Time Intervention (CTI)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507
View directory record Official record
Conditions
Weight Gain
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCT02624167
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
NW-3509A, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Garden Grove, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia

NCT00391677
View directory record Official record
Conditions
Schizophrenia
Interventions
Social skills training with attention shaping procedures, Social skills training without attention shaping
Behavioral
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Monmouth Junction, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 5, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

ITI-007 (Lumateperone Tosylate) for Schizophrenia

NCT03817528
View directory record Official record
Conditions
Schizophrenia
Interventions
ITI-007
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Reducing Internalized Stigma in People With Serious Mental Illness

NCT01259427
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
Interventions
Ending Self Stigma (ESS), Health and Wellness Group
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

NCT00087542
View directory record Official record
Conditions
Hallucinations, Psychoses, Parkinson's Disease
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2005 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

The Family VOICE Study

NCT01804582
View directory record Official record
Conditions
Autism, Aggression, Bipolar Disorder, Psychotic Disorders
Interventions
Family Navigator consultation
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Years to 15 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Alcohol Use Disorders in Schizophrenia

NCT00280813
View directory record Official record
Conditions
Schizophrenia, Mood Disorders, Alcohol Abuse, Alcohol Dependence
Interventions
Supportive Treatment in Addiction Recovery (STAR)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

NCT00208143
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
Interventions
Quetiapine, Risperidone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCT02392468
View directory record Official record
Conditions
Schizophrenia, Alzheimer Disease
Interventions
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • Eatontown, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

NCT02469155
View directory record Official record
Conditions
Schizophrenia
Interventions
ITI-007, Risperidone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Determining Metabolic Effects of Valproate and Antipsychotic Therapy

NCT00167934
View directory record Official record
Conditions
Schizophrenia
Interventions
Valproate, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 5, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

NCT00589914
View directory record Official record
Conditions
Schizophrenia
Interventions
RISPERDAL CONSTA, Paliperidone palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 5, 2026, 9:03 PM EDT
Suspended No phase listed Observational

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

NCT03513549
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Loxapine 10 MG
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 5, 2026, 9:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

NCT01384604
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 70 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 5, 2026, 9:03 PM EDT